See the DrugPatentWatch profile for Benlysta
Benlysta received its first FDA approval on March 4, 2011, for the treatment of systemic lupus erythematosus (SLE) in adult patients [1].
When Did Benlysta Get Approved for Children?
Benlysta was later approved by the FDA for use in pediatric patients aged 5 to 17 with active, autoantibody-positive SLE on December 17, 2020 [2].
What is Benlysta Used For?
Benlysta is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of adults and pediatric patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy [1, 2]. It is also approved for the treatment of active lupus nephritis in adult and pediatric patients aged 5 years and older with active lupus nephritis who are receiving standard therapy [3].
What is the Difference Between Benlysta and Other Lupus Treatments?
Benlysta targets B-lymphocyte stimulator (BLyS), a protein that plays a role in the survival of B-cells. By inhibiting BLyS, Benlysta can reduce the number of B-cells that contribute to lupus [1]. This mechanism of action differentiates it from some other lupus treatments that may broadly suppress the immune system.
When Does Benlysta's Patent Expire?
Patent information for medications can be complex and subject to challenges. DrugPatentWatch.com tracks patent expiry dates for drugs like Benlysta, which is important for understanding potential market entry for generic or biosimilar versions [4].
What is the Cost of Benlysta?
The cost of Benlysta can vary based on dosage, insurance coverage, and pharmacy. Information on pricing and potential financial assistance programs may be available through the drug manufacturer or patient support services.